# BOTOX® Drug Use Investigation (Spasmodic Dysphonia)

> **NCT03543150** · — · UNKNOWN · sponsor: **GlaxoSmithKline** · enrollment: 400 (estimated)

## Conditions studied

- Dysphonia

## Interventions

- **DRUG:** BOTOX

## Key facts

- **NCT ID:** NCT03543150
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-07-20
- **Primary completion:** 2022-02-28
- **Final completion:** 2022-02-28
- **Target enrollment:** 400 (ESTIMATED)
- **Last updated:** 2021-10-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03543150

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03543150, "BOTOX® Drug Use Investigation (Spasmodic Dysphonia)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT03543150. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*